Allos Ventures, an Indianapolis-based venture capital firm focused on Midwest technology companies, announced Tuesday that it has raised $40 million for its latest fund, Allos III, and has begun ...

CAMBRIDGE, Mass., Aug. 21, 2025 /PRNewswire/ -- Allos Pharma Inc., announces key milestones advancing its mission to deliver effective treatments for Autism Spectrum Disorder (ASD), Fragile X Syndrome ...

ALLOS (B3: ALOS3) announces its results for 1Q26. The Company held interests in 46 shopping centers, totaling 1,931 thousand sqm of Total GLA and 1,262 thousand sqm of Owned GLA. The Company also ...

INDIANAPOLIS (Inside INdiana Business) — Indianapolis-based Allos Ventures has announced the first closing of its latest fund, Allos IV. The venture capital firm says the fund will continue its focus ...

Allos Therapeutics anticipates a January commercial launch for Folotyn, the first and only drug currently approved by the FDA for relapsing or refractory peripheral T-cell lymphoma (rrPTCL). A ...

Allos Ventures makes investing in early-stage companies look easy. National data shows it is not. According to a 2018 Harvard Business School study, 75 percent of venture-backed startups fail. So one ...

AMAG Pharmaceuticals, Inc. /quotes/zigman/107237/quotes/nls/amag AMAG +3.59% and Allos Therapeutics, Inc. /quotes/zigman/81880/quotes/nls/alth ALTH +17.48% today ...

- Allos to Receive $50 Million Upfront Payment and Retain Full Commercialization Rights to FOLOTYN in U.S. and Canada; Mundipharma to Co-Develop and Commercialize in the Rest of World - - Allos to ...

TEL AVIV (MarketWatch) -- Allos Therapeutics Inc., the Westminster, Colo., biopharma focused on cancer drugs, agreed to be acquired by Spectrum Pharmaceuticals Inc. for $1.82 cash plus a contigent ...

BANGALORE, Sept 25 (Reuters) - Allos Therapeutics said U.S. health regulators granted accelerated approval for its drug Folotyn to treat one of the most deadly and aggressive types of white blood cell ...